Ray Therapeutics receives EMA PRIME status for gene therapy

Thursday, April 30, 2026Salong DebbarmaView original

Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).

Read the full article on the original site.